About Alacris Pharmaceuticals
Alacris Pharmaceuticals is a pharmaceutical technology company first incorporated in Berlin, Germany on Sept. 24, 2008. The company is based on novel translational medicine/systems biology technology developed at the Max Planck Institute for Molecular Genetics in Berlin coupled with preferential access to the world’s most cost effective sequencing and genotyping technology. The management team is composed of highly experienced pharmaceutical executives who have substantial experience across all relevant aspects of the pharmaceutical value chain. The scientific founders are among the world’s foremost experts in sequencing technology, systems biology and bio-medicine.
Alacris Pharmaceuticals plans to use its technology platform to apply the latest discoveries and knowledge about the biological mechanisms of disease to some of the most important problems facing patients, clinicians, and pharmaceutical companies today. Using the company’s proprietary technology platform coupled with its capabilities for intensive and cost effective genotyping the company will focus on helping pharmaceutical companies in three key areas: identifying which patients will benefit from which therapies, identifying diagnostic markers which more effectively gauge efficacy or toxicity in clinical trials, and identifying therapeutic areas of application for pre-clinical drug discovery projects.
In addition Alacris Pharmaceuticals also plans to use the extensive pharmaceutical expertise of its management team to in-license early lead to phase I programs, develop the programs in a stratified fashion using the company’s proprietary technology platform and then to out-license them.
